Abstract
Abnormal gene promoter methylation contributes to deregulate gene expression of hematopoietic progenitors in myelodysplastic syndromes (MDS). We analyzed the gene expression profile of myelodysplastic and normal CD34+ hematopoietic stem cells (HSCs) treated in vitro with decitabine. We identified a list of candidate tumor suppressor genes, expressed at low levels in MDS HSCs and induced by hypomethylating treatment only in MDS, but not in normal HSCs. Real-time RT-PCR confirmed reduced CD9 expression in MDS CD34+ and bone marrow mononuclear cells, compared to normal controls. CD9 was specifically up-regulated by decitabine treatment in myelodysplastic CD34+ cells.
Lingua originale | English |
---|---|
pagine (da-a) | 465-471 |
Numero di pagine | 7 |
Rivista | Leukemia Research |
Volume | 35 |
DOI | |
Stato di pubblicazione | Pubblicato - 2011 |
Keywords
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antigens, CD29
- Antigens, CD34
- Antimetabolites, Antineoplastic
- Azacitidine
- Cluster Analysis
- DNA Methylation
- Female
- Gene Expression
- Gene Expression Profiling
- Hematopoietic Stem Cells
- Humans
- Male
- Middle Aged
- Myelodysplastic Syndromes
- Oligonucleotide Array Sequence Analysis
- Promoter Regions, Genetic
- Reverse Transcriptase Polymerase Chain Reaction
- Young Adult